Glucagon-like peptide-1 (GLP-1) is a gut incretin hormone that has an antioxidative protective effect on various tissues. Here, we determined whether GLP-1 has a role in the pathogenesis of diabetic nephropathy using nephropathyresistant C57BL/6-Akita and nephropathy-prone KK/Ta-Akita mice. By in situ hybridization, we found the GLP-1 receptor (GLP-1R) expressed in glomerular capillary and vascular walls, but not in tubuli, in the mouse kidney. Next, we generated C57BL/6-Akita Glp1r knockout mice. These mice exhibited higher urinary albumin levels and more advanced mesangial expansion than wild-type C57BL/6-Akita mice, despite comparable levels of hyperglycemia. Increased glomerular superoxide, upregulated renal NAD(P)H oxidase, and reduced renal cAMP and protein kinase A (PKA) activity were noted in the Glp1r knockout C57BL/6-Akita mice. Treatment with the GLP-1R agonist liraglutide suppressed the progression of nephropathy in KK/Ta-Akita mice, as demonstrated by reduced albuminuria and mesangial expansion, decreased levels of glomerular superoxide and renal NAD(P)H oxidase, and elevated renal cAMP and PKA activity. These effects were abolished by an adenylate cyclase inhibitor SQ22536 and a selective PKA inhibitor H-89. Thus, GLP-1 has a crucial role in protection against increased renal oxidative stress under chronic hyperglycemia, by inhibition of NAD(P)H oxidase, a major source of superoxide, and by cAMP-PKA pathway activation.
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Kidney International advance online publication, 23 October 2013; doi:10.1038/ki.2013.427 KEYWORDS: diabetic nephropathy; glucagon-like peptide-1; oxidative stress Diabetic nephropathy (DN) is a serious complication of diabetes and the leading cause of end-stage renal disease in developed countries. Recent evidence indicates that oxidative stress has a central role in the development and progression of DN. 1, 2 The increase in systemic oxidative stress becomes prominent from the incipient stage of DN. 3 In the kidney, reactive oxygen species (ROS) including superoxide anion (O 2 -) are excessively produced by chronic hyperglycemia, leading to increased levels of renal oxidative stress. NAD(P)H oxidase is the most important source of superoxide anion, [4] [5] [6] [7] and this enzyme is shown to be upregulated in the diabetic kidney. 5, [8] [9] [10] A recent in vitro study using human HEK293 cells demonstrated that NAD(P)H oxidase NOX1-dependent ROS production is reduced by the elevation of cAMP and subsequent activation of protein kinase A (PKA). 11 Furthermore, treatment with cAMP-elevating agents such as isoproterenol and forskolin normalized the levels of NAD(P)H oxidase activity and superoxide in aortic vascular smooth muscle cells of spontaneously hypertensive rats. 12 Thus, the cAMP-PKA pathway appears to work as an important inhibitory factor for NAD(P)H oxidase-dependent production of ROS or superoxide.
Glucagon-like peptide-1 (GLP-1) is a gut incretin hormone that stimulates insulin secretion from pancreatic b-cells in a glucose-dependent manner. 13 Activation of the GLP-1 receptor (GLP-1R) stimulates adenylate cyclase and enhances the production of cAMP, the primary effector of GLP-1-induced insulin secretion. 13, 14 Furthermore, increased levels of cAMP activate PKA or cAMP-regulated guanine nucleotide exchange factor II (Epac2), and contribute to mediating various physiological actions including insulin secretion. 14, 15 The GLP-1R is expressed in pancreatic b-cells and in multiple extrapancreatic tissues including the gut, brain, heart, lung, and kidney. 16, 17 Given the evidence indicating that cAMP and PKA pathways link to antioxidative effects, it is likely that GLP-1 protects various tissues from oxidative injury. However, the roles of GLP-1 in the kidney and DN have not been fully elucidated. First, the precise localization of GLP-1R in the kidney remains unclear. Second, it is unknown whether gain or loss of GLP-1R signaling modulates renal function and the progression of renal injury under conditions of chronic hyperglycemia.
In the present study, we investigated the role of endogenous GLP-1R signaling in DN. First, we examined the localization of GLP-1R in the mouse kidney by in situ hybridization and reverse transcriptase polymerase chain reaction (RT-PCR) analysis. Next, we studied two Ins2 Akita diabetic mouse models showing different susceptibility to the development and progression of DN, DN-resistant C57BL/6-Ins2
Akita (C57BL/6-Akita), and DN-prone KK/Ta-Ins2
Akita (KK/Ta-Akita). 18, 19 We examined the renal phenotypes of C57BL/6-Akita mice with GLP-1R deficiency, and in complementary experiments, we tested whether a GLP-1R agonist, liraglutide, ameliorates nephropathic changes in KK/ Ta-Akita mice that develop progressive DN. 18 
RESULTS

Renal expression and localization of the Glp1r in mice
As recent studies have highlighted the lack of sensitivity and specificity of multiple GLP-1R antisera, 20, 21 we used in situ hybridization analysis to assess Glp1r expression in kidneys of 8-week-old male C57BL/6-wild-type (C57BL/6-WT) mice. As shown in Figure 1 , Glp1r mRNA transcripts were localized along glomerular capillary walls and throughout vascular walls, but not in tubules and collecting ducts, in the kidney.
In particular, the in situ hybridization analysis revealed that the Glp1r is predominantly expressed in renal blood vessels. To further verify these findings, we examined Glp1r mRNA expression in isolated enriched preparations of glomeruli, tubuli, and renal arteries. Consistent with the results of in situ hybridization analysis, Glp1r mRNA transcripts were detected in RNA from glomeruli and to a greater extent in renal arteries, but not in tubuli (Figure 1e and f).
Generation of GLP-1R-and insulin-deficient C57BL/6-Akita mice and basic metabolic measurements
We next confirmed the lack of Glp1r expression in newly generated lines of Akita mice lacking the Glp1r. Figure 2a shows the data of RT-PCR analysis in 30-week-old GLP-1R-deficient C57BL/6 strain mice (Glp1r À / À ) and GLP-1R-present littermates (Glp1r þ / þ ). A complete absence of renal glomerular Glp1r mRNA was confirmed in Glp1r À / À mice. The levels of glomerular Glp1r mRNA transcripts were similar between nondiabetic C57BL/6-WT and diabetic C57BL/6-Akita mice. As shown in Figure 2b , GLP-1R deficiency did not affect islet topography and the number of insulin þ cells in the C57BL/6-Akita mice. Table 1 shows biochemical and physiological parameters at 30 weeks of age in the WT and Akita Glp1r À / À and Glp1r þ / þ mice. GLP-1R deficiency did not affect plasma levels of active GLP-1, glucose, and insulin. Furthermore, there were no significant differences in body weight, systolic blood pressure, blood urea nitrogen, and plasma lipids between Glp1r þ / þ and Glp1r À / À C57BL/6-Akita mice. Interestingly, Glp1r
À / À C57BL/6-Akita mice exhibited significantly higher levels of urinary albumin, glomerular filtration rate (GFR), and kidney weight relative to Glp1r þ / þ C57BL/6-Akita mice. The mild changes in the renal phenotype of Glp1r À / À C57BL/6-Akita mice were detected by 15 weeks of age (data not shown), and these mice developed overt renal diabetic changes by 30 weeks of age. In contrast, we did not observe similar changes in renal parameters in Glp1r þ / þ C57BL/6-WT mice.
Renal glomerular histopathology in Glp1r
À / À C57BL/6-Akita mice Figure 3 shows glomerular histopathology at 30 weeks of age in Glp1r þ / þ versus Glp1r À / À C57BL/6-WT and C57BL/ 6-Akita mice. Interestingly, periodic acid-Schiff (PAS) staining examination revealed increased mesangial expansion in Glp1r À / À C57BL/6-Akita mice as compared with Glp1r
C57BL/6-Akita mice. Nondiabetic C57BL/6-WT mice displayed normal glomerular histology. Obvious tubulointerstitial injury was not observed in any groups (data not shown). Fibronectin (FN) is an extracellular matrix component and is present along glomerular basement membranes. An increase in FN deposition is observed during glomerular injury, 22 and hence FN is used as a marker of diabetic 
þ / þ C57BL/6-Akita mice, Glp1r À / À C57BL/6-Akita mice displayed significantly increased FN accumulation in glomerular capillary walls (Figure 3a and c) . WT1 staining analysis revealed a significant reduction of podocyte number in Glp1r À / À C57BL/6-Akita mice relative to Glp1r þ / þ C57BL/6-Akita mice (Figure 3a  and d) . Furthermore, through electron microscopic analysis, we observed irregular thickening of the glomerular basement membrane (GBM) in Glp1r À / À C57BL/6-Akita mice (Figure 3a) . Morphometric analysis revealed a significant increase in GBM thickness in Glp1r -À / À C57BL/6-Akita mice (Figure 3e ).
Renal changes in cAMP and PKA activity levels in Glp1r À / À C57BL/6-Akita mice Figure 4 shows renal cAMP and PKA activity levels at 30 weeks of age in Glp1r þ / þ versus Glp1r À / À C57BL/6-WT and C57BL/6-Akita mice. Renal levels of both cAMP and PKA activity were markedly reduced in Glp1r À / À C57BL/6-WT and Glp1r À / À C57BL/6-Akita mice. In contrast, levels of renal cAMP and PKA activity were similar in Glp1r þ / þ mice. These findings indicate that renal cAMP and PKA activity are regulated by the presence or absence of the Glp1r, independent of levels of glycemia in mice.
Renal changes in oxidative stress markers in Glp1r
The degree of renal oxidative stress was assessed using dihydroethidium (DHE) histochemistry and thiobarbituric acid-reactive substance (TBARS) assay at 30 weeks of age in Glp1r þ / þ versus Glp1r À / À C57BL/6-WT and C57BL/6-Akita mice. As shown in Figure 5a and b, the glomeruli in C57BL/6-Akita diabetic mouse groups showed intense DHE fluorescence, indicating increased glomerular superoxide production. Notably, glomerular DHE fluorescence was stronger in kidneys from Glp1r À / À C57BL/6-Akita mice. Renal levels of TBARS, a sensitive marker of oxidative stress, were elevated in C57BL/6-Akita diabetic mouse groups ( Figure 5e ) and significantly greater in Glp1r À / À C57BL/6-Akita mice, suggesting that GLP-1R deficiency contributes to increasing renal oxidative stress in the setting of diabetes ( Figure 5e ). Recent experimental studies have reported that NAD(P)H oxidase NOX4 component is a major source of renal superoxide in the diabetic state, 9 and that chronic hyperglycemia enhances renal activity of NAD(P)H oxidase. 10, 23 Consistent with these findings, we observed that glomerular NOX4 expression and renal NAD(P)H oxidase activity were increased in C57BL/6-Akita diabetic mice relative to nondiabetic mice ( Figure 5a , c and f). Reduction of glomerular NO accelerates the progression of albuminuria and mesangial expansion in diabetic mice. [24] [25] [26] Therefore, we examined glomerular NO levels by evaluation of the fluorescent intensity of the diaminofluorescein-2 diacetate reaction. As shown in Figure 5a and d, C57BL/6-Akita diabetic mice showed decreased glomerular NO levels. Semiquantitative analysis of glomerular NO fluorescence intensity revealed significantly lower glomerular NO levels in diabetic Glp1r À / À C57BL/6-Akita mice ( Figure 5d ). In contrast, there was no significant difference in glomerular NO levels between the two C57BL/6-WT nondiabetic mouse groups (Figure 5a and d).
Renal glomerular expression of fibrogenic cytokines in
Thrombospondin-1 (TSP-1) is a homeotrimetric glycoprotein identified as an endogenous activator of transforming growth factor-b1 (TGF-b1). 27 TGF-b1 and connective tissue growth factor (CTGF) are well-known fibrogenic cytokines implicated in the development of renal hypertrophy and mesangial expansion in diabetic nephropathy. 28, 29 Hence, we In contrast, these glomerular changes were not observed in nondiabetic Glp1r þ / þ C57BL/ 6-WT mice that displayed normal glomerular histology.
Effects of a GLP-1R agonist liraglutide on renal function, histological changes, and oxidative stress in DN-prone KK/TaAkita mice
We next assessed whether the activation of GLP-1R using the GLP-1R agonist liraglutide suppresses the progression of renal injury in KK/Ta-Akita mice, a mouse model of progressive DN. 18 Mice were treated with liraglutide alone or in combination with an adenylate cyclase inhibitor SQ22536 or a selective PKA inhibitor H-89. Table 2 shows physiological and biochemical data after a 4-week treatment period in 8-week-old KK/Ta-Akita mice. Although all groups of mice were similar with respect to body weight, systolic blood pressure, blood glucose, plasma insulin, blood urea nitrogen, plasma creatinine, and serum lipids, mice treated with liraglutide alone exhibited lower levels of urinary albumin-to-creatinine ratio, GFR, and kidney weight. These results suggest that liraglutide attenuates the development of diabetic renal changes such as overt albuminuria, glomerular hyperfiltration, and renal hypertrophy without affecting the severity of diabetes and diabetesrelated factors. Furthermore, SQ22536 and H-89 abolished the renal protective effects of liraglutide.
We next examined changes in renal histopathology, oxidative stress, NO, cAMP, and PKA activity after a 4-week treatment with liraglutide, with or without SQ22536 or H-89, in 8-week-old KK/Ta-Akita mice. As shown in Figure 7a (PAS staining) and 7b, moderate mesangial expansion was observed in vehicle-treated KK/Ta-Akita mice; however, mesangial expansion was reduced by liraglutide administration. FN accumulation in glomerular capillary walls was significantly diminished in the KK/Ta-Akita mice treated with liraglutide alone (Figure 7a and c) . Furthermore, the KK/Ta-Akita mice treated with liraglutide alone exhibited higher podocyte number (Figure 7a and d) and lower GBM thickness (Figure 7a and e) than vehicle-treated KK/Ta-Akita mice. Notably, the amelioration of glomerular histopathological damage by liraglutide was eliminated in KK/Ta-Akita Figure 8 shows renal cAMP and PKA activity levels in 8-week-old KK/Ta-Akita mice. KK/Ta-Akita mice treated with liraglutide alone for 4 weeks displayed higher renal levels of cAMP and PKA activity than vehicle-treated KK/Ta-Akita mice. In contrast, renal cAMP did not increase after treatment with SQ22536, and was only modestly increased in mice treated with H-89, whereas PKA activity levels were not increased in kidneys of KK/Ta-Akita mice treated with liraglutide in combination with SQ22536 or H-89. Figure 9 shows the degree of renal oxidative stress and glomerular NO levels in 8-week-old KK/Ta-Akita mice. The treatment with liraglutide alone for 4 weeks significantly reduced glomerular levels of superoxide and NOX4 expression and increased glomerular NO levels in KK/Ta-Akita mice (Figure 9a-d) . Furthermore, we observed significant reduction of renal TBARS and NAD(P)H oxidase activity levels in the KK/Ta-Akita mice treated with liraglutide alone as compared with vehicle-treated KK/Ta-Akita mice (Figure 9e and f) . In contrast, the renoprotective effects of liraglutide were abolished by coadministration of either SQ22536 or H-89.
DISCUSSION
The present study, using in situ hybridization and RT-PCR analyses, demonstrates that Glp1r mRNA transcripts are localized in glomerular capillary walls and throughout vascular walls, but not in tubules and collecting ducts, in the mouse kidney. More recently, Panjwani et al. 20 have demonstrated that commercially available widely used GLP-1R antisera are neither sensitive nor specific, and detect comparable immunoreactive bands in tissue extracts of both Glp1r þ / þ and Glp1r À / À mice. 20 Similar concerns surrounding the use of commercially available GLP-1R antisera have been raised by other groups. 21 Hence, to avoid the pitfalls inherent in using antisera with suboptimal sensitivity and specificity, we used in situ hybridization and RT-PCR analysis to assess the expression and localization of Glp1r expression within the kidney.
To explore whether the presence or absence of GLP-1R signaling has a crucial role in the development and progression of DN, we disrupted the Glp1r gene in the DN-resistant mouse model C57BL/6-Akita and investigated its renal phenotype. The C57BL/6-Akita mice exhibit less oxidative and diabetic renal damage despite having relatively high renal activity of NAD(P)H oxidase, a major source of superoxide, because superoxide dismutase antioxidant defense system works well in their kidneys. 18 Interestingly, the present data indicate that loss of the GLP-1R induces the upregulation of glomerular NOX4 expression and further elevation of renal NAD(P)H oxidase activity, resulting in elevation of glomerular superoxide and renal oxidative stress levels in the C57BL/6-Akita mice. These renal alterations secondary to GLP-1R deficiency contribute to the development of overt DN in the DN-resistant C57BL/6-Akita mice, as evidenced by pronounced mesangial expansion, podocyte reduction, and GBM thickening. Therefore, it is conceivable that loss of GLP-1 action resulting from GLP-1R deficiency directly reduces the renal antioxidant defense capacity against increased oxidative stress under hyperglycemic conditions. Furthermore, consistent with the lack of a significant islet phenotype arising in other insulin-resistant diabetic murine models lacking the Glp1r such as the ob/ob Glp1r À / À mouse, 30 we found that GLP-1R deficiency does not affect insulin and GLP-1 secretion, glucose tolerance, islet topography, or other metabolic factors in the C57BL/6-Akita mice.
To further elucidate the mechanism underlying renal alterations observed in the Glp1r À / À C57BL/6-Akita mice, we investigated renal cAMP-PKA, an important second Kidney International messenger system downstream of GLP-1R activation. Our results indicate that GLP-1R deficiency causes marked basal reduction of intrarenal cAMP formation and PKA activity in the C57BL/6-Akita mice. Given the evidence that cAMP and PKA represent important inhibitory factors for NAD(P)H oxidase, 11, 12, 31, 32 it is conceivable that Glp1r À / À C57BL/6-Akita mice greatly increased their renal NAD(P)H oxidase activity owing to reduction of cAMP levels in the setting of chronic hyperglycemia, resulting in renal superoxide overproduction beyond their superoxide dismutase superoxide-scavenging capacity.
It is well known that oxidative stress upregulates fibrogenic cytokines such as TGF-b1 and CTGF, leading to mesangial cell proliferation and extracellular matrix production. 29, 33 Our study indicated that Glp1r À / À C57BL/6-Akita mice have higher renal expression levels of TGF-b1 and CTGF in addition to TSP-1, an endogenous activator of TGFb1. Hence, increased activity of these fibrogenic cytokines may contribute to the pronounced mesangial expansion observed in the Glp1r À / À C57BL/6-Akita mice. Another interesting finding observed in the kidneys of Glp1r À / À C57BL/6-Akita mice is glomerular NO reduction. Excessive superoxide anion could reduce glomerular NO levels by scavenging NO from glomerular endothelial cells. 34, 35 NO is an important regulator for charge selectivity in the endothelial cell layer, and therefore glomerular NO reduction could enhance the permselectivity of plasma albumin through glomerular capillary wall. Arcos et al. 36 showed that chronic NO inhibition impairs glomerular charge selectivity barrier and causes albuminuria in rats. Furthermore, experimental studies of diabetic rats and mice indicated that renal NO reduction is associated with the development of renal histologic lesions, 37 and that NO deficiency by endothelial NO synthase knockout causes glomerular endothelial injury and overt albuminuria. 25 Taken together, it is plausible that glomerular NO reduction triggered by excessive oxidative stress contributed to increased albuminuria in Glp1r À / À C57BL/6-Akita mice. Recently, we generated a mouse model of progressive DN: KK/Ta-Akita. In contrast to C57BL/6-Akita mice, the KK/TaAkita mice show high susceptibility to DN, as evidenced by the development of severe albuminuria and prominent mesangial expansion. 18 We reported that the diabetic renal changes in the KK/Ta-Akita mice are attributable to excessive renal oxidative stress. 18 In this regard, the KK/Ta-Akita mouse represents a useful model to assess whether activation of GLP-1R signaling suppresses the progression of DN via amelioration of renal oxidative stress. The present data clearly show that the GLP-1R agonist liraglutide ameliorates oxidative stress by elevating cAMP and PKA activity levels, downregulating NOX4, and reducing NAD(P)H oxidase activity in the kidneys of KK/Ta-Akita mice. Furthermore, liraglutide suppresses the progression of diabetic renal pathology, as evidenced by renal alterations such as reduced albuminuria, attenuated mesangial expansion, enhanced glomerular NO levels, and improved glomerular hyperfiltration and renal hypertrophy, in KK/Ta-Akita mice. It is noteworthy that renal improvement was induced without major changes in insulin secretion, glucose tolerance, and other metabolic factors. Collectively, these findings support the concept that GLP-1R signaling directly exerts antioxidative and protective effects on the hyperglycemic kidney. Furthermore, the beneficial actions of liraglutide were inhibited by the adenylate cyclase inhibitor SQ22536 and the selective PKA inhibitor H89, consistent with a critical role for cAMP and PKA-dependent pathways downstream of GLP-1R activation in renal protection. However, we cannot rule out the possibility that other signaling pathways may also be involved, given the possibility for 'off-target' inhibition when these and other inhibitors are used at high concentrations.
Consistent with the gain-of-function studies reported here, GLP-1R agonists such as exendin-4 and liraglutide attenuated diabetic renal injury, including mesangial expansion and albuminuria through the protection of glomerular endothelial cells, 38 reduction of renal oxidative stress, 39 and suppression of renal inflammatory cytokines 40 in high-dose streptozotocin (STZ)-induced diabetic rats and mice. However, there are several important differences in renal outcomes between our Akita mouse models and the STZ diabetic animals. Notably, albuminuria in the STZ rats is more severe than that in KK/Ta-Akita diabetic mice, exceeding 2.0 mg/24 h. 39, 40 Furthermore, STZ is known to induce nonspecific toxicity in multiple organs including kidney, liver, and arteries, especially when it is used at high doses. 41, 42 Therefore, it is likely that these deleterious effects of STZ caused greater kidney damage and more severe albuminuria in the STZ rats. More importantly, it has been shown that STZ stimulates superoxide production 43 and induces robust oxidative stress in the kidneys as compared with spontaneous diabetic mice. 44 In this context, our KK/ Ta-Akita mouse model that develops overt DN without chemicals such as STZ or alloxan provides valuable information regarding the role of GLP-1R signaling in DN arising in the absence of chemically induced renal injury.
Finally, our data support a model for a GLP-1R-dependent intrarenal signaling pathway, as summarized in Figure 10 . The present study provides the first evidence that loss of GLP-1R signaling upregulates renal NAD(P)H oxidase and increases renal oxidative stress, with reduced levels of renal cAMP-PKA activity in the setting of chronic hyperglycemia accentuating the progression of DN. Furthermore, the present study illustrates that GLP-1R agonists suppress the progression of DN through antioxidative actions. These data support the concept of future clinical studies investigating whether renal outcomes will be similarly modified in subjects with diabetic kidney disease.
MATERIALS AND METHODS
Experimental animals and liraglutide treatment C57BL/6-Akita mice are available from SLC (Hamamatsu, Shizuoka, Japan). The generation of Glp1r À / À C57BL/6 mice has been described previously. 45 
Glp1r
À / À C57BL/6-Akita mice were generated using C57BL/6-Akita and Glp1r À / À C57BL/6 mice. Male C57BL/6-WT and C57BL/6-Akita mice with or without GLP-1R deficiency were used for the study. Biochemical and physiological parameters, renal histopathology, and renal oxidative stress markers were examined at 30 weeks of age in these mice. KK/Ta-Akita mice were generated as described previously. 18 Eight-week-old male KK/ Ta-Akita mice were subcutaneously injected with the GLP-1R agonist liraglutide (200 mg/kg per day; Novo Nordisk, Novo Alle, Bagsvaerd, Denmark) either alone or in combination with an adenylate cyclase inhibitor SQ22536 (2 mg/kg per day; Sigma-Aldrich, St Louis, MO) or a selective PKA inhibitor H-89 (2 mg/kg per day; Sigma-Aldrich) administered by retro-orbital injection under light isoflurane anesthesia for 4 weeks. A parallel group of control age-matched male KK/Ta-Akita mice was injected with an equivalent volume of the vehicle (saline). The mice were allowed unrestricted access to standard rodent chow and water. Animal experiments were carried out in accordance with the Animal Welfare Guidelines of Akita University. All procedures were approved by the Committee on Animal Experimentation of Akita University.
Blood and urine parameters Blood glucose was measured on samples obtained after a 6-h daytime fast using Glucocard Diameter (Arkray, Tokyo, Japan). Blood urea nitrogen, plasma creatinine, plasma total cholesterol, and plasma triglycerides were enzymatically measured using an autoanalyzer (Fuji Dry-Chem 5500; Fuji Film, Tokyo, Japan). Urinary albumin excretion was assessed by the determination of albumin-tocreatinine ratio on morning spot urine, as described previously. 46 Plasma active GLP-1 and insulin were determined using a GLP-1 (active) ELISA kit (Shibayagi, Gunma, Japan) and an insulin ELISA kit (Morinaga, Yokohama, Japan), respectively.
Physiological parameters
Systolic blood pressure was measured in conscious trained mice using a noninvasive tail cuff and pulse transducer system (BP-98A; Softron, Tokyo, Japan). GFR was measured by a single-bolus fluorescein isothiocyanate-inulin injection and clearance method, as described previously. 47 In situ hybridization The sense and antisense riboprobes were directed against mouse Glp1r (bp 108-500; GenBank NM_021332) and generated by RT-PCR to amplify a 393-bp fragment. Detailed protocol for in situ hybridization is described in Supplementary Material online.
Isolation of glomeruli and quantitative RT-PCR Glomeruli and tubuli were separated from the renal cortex of 8-week-old male C57BL/6-WT mice by Dynabead perfusion method as reported previously, with some modifications. 48 To further investigate the localization of Glp1r mRNA transcripts in the kidney in addition to in situ hybridization analysis, we performed RT-PCR analysis using total RNA extracted from glomeruli, tubuli, and renal arteries. Furthermore, RT-PCR analysis of glomerular TGF-b1 and CTGF in addition to GLP-1R was performed at 30 weeks of age in male C57BL/6-WT and C57BL/6-Akita mice with or without GLP-1R deficiency, as described previously. 19 
Histologic analysis
The kidneys were perfused via the left ventricle with phosphatebuffered saline, followed by 4% paraformaldehyde in phosphatebuffered saline, removed, and fixed in 4% paraformaldehyde in phosphate-buffered saline overnight at 4 1C. Two-mm-thick paraffin sections were stained with PAS. A semiquantitative score was used to evaluate the degree and extent of glomerular mesangial expansion, as described previously. 18 Podocyte number was evaluated by WT1 immunohistochemistry and calculated using the Weibel-Gomez method, as reported previously. 49, 50 Five mice per group were analyzed, and more than 60 cortical glomeruli were assessed in each mouse. The thickness of GBM was evaluated by electron microscopic examination in five mice per group, as described previously. 18 Immunofluorescence histochemistry, DHE histochemistry, and in situ NO detection Histochemical analysis was performed as described previously. 5, 18, 19, 51 Five mice per group were analyzed, and more than 20 cortical glomeruli were assessed in each mouse. Detailed protocols for immunofluorescence histochemistry, DHE histochemistry, and in situ NO detection are described in Supplementary Material online.
Measurement of renal cAMP and PKA activity levels Kidney lysate was prepared using phosphate-buffered saline-perfused and freshly removed renal cortical tissue, as described previously. 18 Renal cAMP and PKA activity levels were measured in these kidney lysate samples using a DetectX Direct cAMP Immunoassay kit (Arbor Assays, Ann Arbor, MI) and a PKA kinase activity kit (Enzo Life Sciences, Farmingdale, NY), respectively. The levels were expressed as renal cortical cAMP and PKA activity to protein ratio.
Measurement of renal TBARS and NAD(P)H oxidase activity
Renal TBARS levels were measured in renal cortical tissue lysate samples using a TBARS assay kit (Cayman Chemical, Ann Arbor, MI). The levels were expressed as renal cortical TBARS to protein ratio. Renal NAD(P)H oxidase activity was measured in the same samples using a lucigenin-enhanced chemiluminescence assay, as described previously. 10 Enzymatic activity of NAD(P)H was expressed in relative chemiluminescence (light) units (RLU) per 100 mg of protein.
Statistical analysis
All data were presented as means ± s.e.m. Statistical analysis of the data was performed using the GraphPad Prism software (GraphPad, San Diego, CA). Differences between multiple groups were determined by one-way analysis of variance followed by Bonferroni's multiple comparison test.
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